About
Graegis Pharmaceuticals develops topical therapies that use reactive oxygen species scavengers to prevent and manage radiation-induced dermatitis and oral mucositis in cancer patients undergoing radiotherapy.
Explore Graegis Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.